Objective
The main objective of this project is to understand how premature aging of the immune system, specifically T-cell aging, may contribute to the development and progression of T1D, and to explore whether targeting this aging process could lead to a new therapeutic strategy. Specifically, the project aims to determine whether T-cells from individuals with T1D show signs of accelerated aging, such as shortened telomeres and increased inflammatory activity, and whether these features can be reversed or improved by activating the nuclear receptor LRH-1/NR5A2 using a small-molecule compound called BL001. Ultimately, this work may uncover novel biomarkers for early detection and monitoring of disease progression and identify new therapeutic strategies to preserve immune balance and delay or prevent the onset of T1D.
Background Rationale
Type 1 Diabetes (T1D) is an autoimmune disease in which the body’s immune system mistakenly attacks the insulin-producing cells in the pancreas. This process typically begins years before symptoms appear, progressing silently through early stages characterized by the presence of specific autoantibodies. Although it is now possible to detect these early stages, we still lack a deep understanding of the biological mechanisms that drive the disease forward, particularly those involving immune system dysfunction. One emerging area of interest is the concept of T-cell senescence, or immune cell aging. T-cells are central players in the autoimmune attack in T1D, and like all cells, they undergo aging processes that can alter their function. As T-cells age, they lose their ability to properly regulate immune responses and begin to secrete inflammatory molecules that may worsen autoimmune activity. These changes are associated with shortened telomeres—the protective ends of chromosomes that naturally shorten with age and stress—and reduced activity of telomerase, the enzyme that helps maintain telomere length. Recent evidence suggests that telomere shortening, and T-cell senescence may contribute to the immune imbalance seen in T1D, but these processes remain largely unexplored in humans, especially during the early, presymptomatic stages of the disease. This project seeks to fill this gap by characterizing telomere dynamics and T-cell aging in individuals at different stages of T1D. In parallel, the study will test whether targeting the nuclear receptor LRH-1/NR5A2, a molecule known to promote cell survival and limit inflammation, can reverse or slow down T-cell senescence. A small-molecule compound, BL001 has previously shown promising effects in restoring immune tolerance in preclinical models as well as in human immune cells from individuals with T1D. By examining its effects on human T-cells, this project aims to clarify whether immune cell aging can be therapeutically modulated. The rationale behind this research is that understanding and potentially reversing T-cell aging could not only shed light on the mechanisms underlying T1D but also offer a new pathway toward disease-modifying therapies and early detection strategies.
Description of Project
Type 1 Diabetes (T1D) is an autoimmune condition where the body’s immune system mistakenly destroys the insulin-producing cells in the pancreas. While insulin therapy helps manage blood sugar levels, it does not address the root cause of the disease, immune dysfunction. This project explores a largely overlooked mechanism that could be driving this dysfunction: premature aging of T-cells, a key immune cell population responsible for targeting the pancreas. T-cell aging is closely linked to telomere shortening (protective caps at the ends of chromosomes that shorten as cells divide). When telomeres become critically short, T-cells can enter a state called senescence. Senescent T-cells no longer divide and begin to secrete inflammatory molecules, contributing to chronic immune activation. While telomere shortening and senescence have been extensively studied in aging and cancer, their role in autoimmune diseases like T1D remains largely unexplored. This project has two main goals. First, we will study telomere length, telomerase activity (the enzyme that maintains and extends telomeres), and signs of cellular senescence in T-cells from people with T1D. Samples will include individuals at different disease stages, including early preclinical stages where no symptoms are present but immune markers suggest the disease is beginning. Using advanced assays, we will assess whether these immune cells show signs of premature aging and how this correlates with disease progression. Second, we will test whether this process can be slowed or reversed using a small molecule, BL001, which activates a protein called LRH-1/NR5A2. This molecule has previously been shown to promote anti-inflammatory immune responses and protect insulin-producing cells in animal models. In this study, we will treat T-cells from T1D individuals with BL001 and examine whether it improves telomere maintenance, reduces signs of senescence, and lowers the production of pro-inflammatory molecules. We will also use single-cell RNA sequencing to see how gene expression patterns change with treatment, particularly genes related to immune aging and inflammation. If successful, this project could uncover new ways to diagnose T1D earlier and slow its progression. Telomere-based biomarkers might help identify high-risk individuals before symptoms appear, and LRH-1-based therapies could provide a targeted way to restore immune balance without broadly suppressing the immune system. In summary, this study aims to connect immune aging with the development of T1D and test a novel therapeutic approach to intervene early. It represents a promising step toward understanding, and potentially preventing, the immune dysfunction that underlies T1D.
Anticipated Outcome
This research project aims to uncover how aging processes in immune cells, specifically T-cells, might contribute to the onset and progression of T1D, and whether these processes can be reversed or slowed using a novel therapeutic strategy. The anticipated outcome is twofold: first, to gain a clearer understanding of telomere shortening and cellular senescence (a type of irreversible cell aging) in T-cells from individuals at different stages of T1D; and second, to determine whether activating the nuclear receptor LRH-1/NR5A2 using a compound called BL001 can improve the function and longevity of these cells. By studying the immune cells of people who are genetically at risk, newly diagnosed, or living with T1D, it is expected to identify patterns of telomere erosion and T-cell senescence that may reflect the progression of the disease. They also aim to see whether the BL001 treatment can reduce inflammatory behavior in these aging T-cells and possibly restore some of their regulatory capacity. In practical terms, the study could lead to the discovery of new biomarkers that help predict who is likely to develop T1D or how quickly the disease may progress. It could also open the door to a new class of therapies designed not just to treat symptoms but to modify the underlying immune dysfunction driving the disease. Ultimately, this work has the potential to transform how we detect, monitor, and manage T1D, particularly in its earliest stages.
Relevance to T1D
Type 1 Diabetes (T1D) is a lifelong autoimmune disease in which the immune system mistakenly attacks the insulin-producing cells in the pancreas. This leads to a complete dependence on insulin therapy and a heightened risk of serious health complications. Although progress has been made in disease management, there is still no cure, and current treatments do not address the root causes of immune dysfunction. This project directly targets one of the most underexplored aspects of T1D: how immune cell aging, specifically T-cell senescence, might drive disease development and progression. By examining the behavior of T-cells across the earliest and later stages of T1D, researchers hope to uncover how these aging cells might contribute to the immune system’s failure to distinguish “self” from “non-self.” Importantly, the study will also test whether a novel treatment strategy using the compound BL001 can reverse or improve these age-related immune changes. If successful, this could not only lead to new therapies that slow or prevent disease onset but also identify biomarkers that help track disease progression over time. This work is especially relevant for individuals with a family history of T1D or those in early, asymptomatic stages of the disease, groups for whom preventative or early intervention strategies could be life-changing. It also supports the broader goal of moving from disease management to disease modification and, eventually, prevention.